SLIDE 1
BIOPHARMOS: NEW OPPORTUNITIES IN BIOTECHNOLOGY FEB 2012 1
BioPharmos Group goes International.
February 2013
BioPharmos Group Business Area
BioPharmos Group goes International
2
BioPharmos Group goes International. February 2013 BIOPHARMOS: NEW - - PowerPoint PPT Presentation
BioPharmos Group goes International. February 2013 BIOPHARMOS: NEW - - PowerPoint PPT Presentation
BioPharmos Group goes International. February 2013 BIOPHARMOS: NEW OPPORTUNITIES 1 IN BIOTECHNOLOGY FEB 2012 BioPharmos Group Business Area R&D Peptide Synthesis Biotechnological Growth of Rare Plants BioPharmos Group goes
SLIDE 2
SLIDE 3
BioPharmos Group: 25+ years in the biotechnology
1987
Life Science Business of BioPharmos Group established
1995
First biotechnolo- gical product – Vitagmal – manufacture start
2008
Headquarter renamed to BioPharmos LTD, St. Petersburg, Russia
3
2011
30% sales growth a year. Primary Naturals LLC, USA established
2012
170% sales growth a year. Pharmbiotech Oy, Finland established Laureat Grand Prix Europeen de Qualite, Geneva BioPharmos Group goes International
SLIDE 4
Who are our customers?
4
BioPharmos Group goes International
SLIDE 5
5
Why BioPharmos Group products?
Own patented biotechnology allows:
to grow biomass of rare plants in industrial scale to receive high quality material in shorter period of time to suggest products for different industries to provide raw materials with unique features on
customers’ demand
BioPharmos Group goes International
SLIDE 6
6
Plants biomass growth in bioreactors
BioPharmos Group goes International
SLIDE 7
7
BioPharmos Group goes International
SLIDE 8
8
BioPharmos Group biotechnology in use
Vitagmal - biomass extract
- f a subtropical medicinal
plant Polyscias filicifolia
Superior to Ginseng extract in 12 pharmacological parameters
Has the property to reduce the risk of inborn anomalies (RF patent № 2058786)
Included in the Russian
- fficial recommendations for
the prevention of pregnancy complications
BioPharmos Group goes International
SLIDE 9
Why to expand production?
9 large-scale pharmaceuticals projects in Saint-
Petersburg and region with 25.12 billion rub. investment volume started in 2010 (Pharma 2020 Program)
Tough competition makes pharmaceuticals
producers to search for raw materials with unique features
Biotech companies market supply is limited
9
BioPharmos Group goes International
SLIDE 10
Why production in Finland?
Economic situation predictability Innovative industries support on state and local
levels
Russian investments state support program High level of Finnish management Territorial proximity Confidence in quality of Finnish products
10
BioPharmos Group goes International
SLIDE 11